Real-world eligibility for platinum doublet plus immune checkpoint inhibitors in extensive-stage small-cell lung cancer

por Rittberg, Rebekah, Leung, Bonnie, Al-Hashami, Zamzam, Ho, Cheryl
Publicado 2022

Real World Patient Eligibility for Second Line Lurbinectedin Based Treatment in Small Cell Lung Cancer: Understanding Epidemiology and Estimating Health Care Utilization

por Rittberg, Rebekah, Leung, Bonnie, Al-Hashami, Zamzam, Ho, Cheryl
Publicado 2022

Lung cancer screening in the gulf: Rationale and recommendations

por Bennji, Sami M., Jayakrishnan, B., Al-Kindi, Adil H., Al-Jahdhami, Issa, Al-Hashami, Zamzam
Publicado 2022

Real-World Outcomes of Stage IV NSCLC with PD-L1 ≥ 50% Treated with First-Line Pembrolizumab: Uptake of Second-Line Systemic Therapy

por Rittberg, Rebekah, Leung, Bonnie, Shokoohi, Aria, Pender, Alexandra, Wong, Selina, Al-Hashami, Zamzam, Wang, Ying, Ho, Cheryl
Publicado 2023

The Prevalence and Patterns of Toxicity With Immune Checkpoint Inhibitors in Solid Tumors: A Real-World Experience From a Tertiary Care Center in Oman

por Salman, Bushra, AlWard, Nameer M, Al-Hashami, Zamzam, Al-Sharqi, Hadil, Al-Sayegh, Hasan, Burney, Ikram A
Publicado 2023

Alternate Pembrolizumab Dosing Interval in Advanced NSCLC with PD-L1 TPS ≥ 50%: 3 Weekly Compared to 6 Weekly Dosing

por Jones, Lauren, Rittberg, Rebekah, Leung, Bonnie, Shokoohi, Aria, Pender, Alexandra, Wong, Selina, Al-Hashami, Zamzam, Wang, Ying, Ho, Cheryl
Publicado 2022

Improved uptake and survival with systemic treatments for metastatic non-small cell lung cancer: younger versus older adults

por Leung, Bonnie, Shokoohi, Aria, Al-Hashami, Zamzam, Moore, Sara, Pender, Alexandra, Wong, Selina K., Wang, Ying, Wu, Jonn, Ho, Cheryl
Publicado 2023

Effect of targeted therapy and immunotherapy on advanced nonsmall‐cell lung cancer outcomes in the real world

por Shokoohi, Aria, Al‐Hashami, Zamzam, Moore, Sara, Pender, Alexandra, Wong, Selina K., Wang, Ying, Leung, Bonnie, Wu, Jonn, Ho, Cheryl
Publicado 2021

Hepatocellular Carcinoma in Oman: An analysis of 284 cases

por Al-Naamani, Khalid, Al-Hashami, Zamzam, Al-Siyabi, Omar, Al-Moundri, Mansour, Al-Bahrani, Bassim, Al-Sinani, Siham, Al-Zakwani, Ibrahim, Omar, Heba, Al-Busafi, Said A., Al-Zuhaibi, Haifa, AlMamari, Abdullah, Kamath, Bola R., Al-Kalbani, Abdullah, Burney, Ikram Ali
Publicado 2020